Vericel Co. (NASDAQ:VCEL) Receives Consensus Recommendation of “Buy” from Brokerages

Vericel Co. (NASDAQ:VCEL) has been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $57.71.

VCEL has been the subject of a number of analyst reports. Canaccord Genuity Group initiated coverage on shares of Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price objective for the company. Truist Financial raised their price objective on shares of Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. HC Wainwright raised their target price on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. BTIG Research cut their price objective on Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a report on Monday, July 15th. Finally, StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th.

Vericel Trading Up 1.4 %

NASDAQ VCEL opened at $42.87 on Friday. The company’s fifty day simple moving average is $45.03 and its 200-day simple moving average is $46.51. Vericel has a 52 week low of $32.28 and a 52 week high of $54.10. The stock has a market cap of $2.08 billion, a P/E ratio of -4,287.00 and a beta of 1.67.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The business had revenue of $52.70 million during the quarter, compared to analyst estimates of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. On average, research analysts expect that Vericel will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling at Vericel

In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the sale, the chief executive officer now owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at $454,960. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,166 shares of company stock worth $1,200,764. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. MCF Advisors LLC lifted its stake in Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares during the period. International Assets Investment Management LLC increased its holdings in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares in the last quarter. CWM LLC increased its holdings in Vericel by 319.0% in the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after buying an additional 504 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares during the period. Finally, Nisa Investment Advisors LLC grew its stake in shares of Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 220 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.